A Phase 2 Randomized, Double-blind, Placebo-controlled Study Evaluating the Prophylactic use of Tocilizumab to Prevent Cytokine Release Syndrome with JNJ-79635322 (Ramantamig) administration in Participants with Relapsed or Refractory Multiple Myeloma

Trial information

Medical condition

R/R MM

Trial phase

Phase 2

Sponsor

Janssen Research & Development, LLC

Start date

01/09/2026

Main objective

Proportion of participants alive and free of treatment ASTCT grade ≥2 CRS without the use of intervening treatment by the end of day 28 from JNJ-79635322 step up dose

Locations and Contact points